Picture Kentro Design Corporate and Web Design Berlin 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5562 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 29 30 31 ... 54 55 56  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Coramaze Technologies–SEVERAL: investment, 201402 seed funding round €1m co-led by HTGF + Seed Capital Dortmund 2014-02-12
Horizon Discovery–Haplogen: cell lines, 201402– distribution ww of cell lines + related products by Horizon 2014-02-12
MyoPowers–Truffle Capital: investment, 201402 existent investment listed on Truffle web site 2014-02-12
Symetis–Truffle Capital: investment, 201402 existent investment listed on Truffle web site 2014-02-12
Insilico Biotechnology–Pharmacelsus: drug development services, 201402– collab offering joint services for preclinical characterisation of APIs 2014-02-10
L’Oréal–Evolva: biosynthetic production technology, 201402– collab developm yeast fermentation technology to produce cosmetic ingredients 2014-02-10
Werum–Körber: investment, 201402– acquisition of newly formed Werum IT Solutions AG by Körber Medipak 2014-02-10
Anergis–SEVERAL: investment, 201402 financing round CHF8m co-led by Sunstone Capital + BioMedInvest + Renaissance PME/Vinci Capital 2014-02-05
Mologen–SEVERAL: investment, 201402 capital increase €15.7m gross proceeds 1,541,244 shares €10.2/share 2014-02-05
Agenus–SEVERAL: invesment, 201402 public offering $60m net $56m 19.335m+2.9m shares $2.7/share 2014-02-04
Bayer–Helmholtz: cancer research, 201402– collab strategic alliance 5y with DKFZ planned combined investment of up to €30m 2014-02-04
General Electric–Definiens: image analysis s/w, 201402– supply automated solutions to Clariant Diagnostic Services for clinical breast cancer testing 2014-02-03
LABiTec–HUMAN Diagnostics Worldwide: investment, 201401 acquisition €na of LAbor BioMedical Technologies GmbH 2014-01-30
Danaher–Univ Münster: mass spectrometry, 201401 collab developm LC/MS/MS method for halal food testing of meat with Institute for Food Chemistry 2014-01-28
Univ Münster–Danaher: mass spectrometer, 201401 supply existent use of AB Sciex QTRAP 5500 system with MRM by Institute for Food Chemistry 2014-01-28
Univ Münster–Danaher: mass spectrometer, 201401 supply existent use of AB Sciex TripleTOF 5600 system by Institute for Food Chemistry 2014-01-28
Trianta Immunotherapies–Medigene: investment, 201401 acquisition 100% for 1m shares worth €4m plus €5.875m milestones in shares or cash 2014-01-27
TiGenix–PharmaCell: investment, 201401 acquisition €5.75m of Dutch manfucturing plant TiGenix BV from TiGenix NV by PharmaCell BV 2014-01-24
Nestlé–Singapore (govt): foods + beverages, 201401– collab food + nutrition r+d in Singapore with A*STAR research institutes 2014-01-22
ACIB–Ionicon: mass spectrometry, 203101 collab existent Ionicon is a partner an ACIB providing PRT-MS technology 2014-01-21
Axel Semrau–Bruker Corp: GC/MS solutions, 201401– collab configuration + sale of automated GC/MS solutions by Semrau using SCION TQ GC/MS systems 2014-01-21
Piqur Therapeutics–SEVERAL: investment, 201401 financing round Series A private placement to new + existing investors 2014-01-21
Biofrontera–SEVERAL: investment, 201401–201402 capital increase €15.3m net with 4.4m news shares 2014-01-20
BPCE–SEVERAL: investment, 201401 launch €120m Seventure Health for Life Capital Fund incl investors Danone + Tereos + Tornier + Natixis + Unigrains 2014-01-20
Qiagen–Trinean: UV/VIS spectrophotometer, 201401– OEM manufacture + supply ww of QIAxpert system by Trinean 2014-01-18
4-Antibody–Agenus: investment, 201401–201402 acquisition $10m in 3.3m shares plus milestones that may exceed $40m in cash or shares 2014-01-13
Boehringer–Argenx: SIMPLE antibody discovery platform, 201401– collab €na pilot research agreement 2014-01-13
Merck (DE)–KineMed: biomarker discovery services, 201401– supply service applying mass spec to identify protein + lipid multiple sclerose markers 2014-01-13
Recepta Biopharma–4-Antibody: Retrocyte Display technology, 201401 collab existent 2014-01-13
Molecular Health–GATC Biotech: DNA sequencing, 201401– supply protocols + support + training + LIMS to Molecular Health Inc 2014-01-10
Probi–Symrise: investment, 201401– mandatory offering SEK40.1/share for all remaining shares of Probi AB after increase of Symrise holdings to 30.03% 2014-01-10
AC Immune–SEVERAL: investment, 201401 financing round Series D CHF20m from existent private investors 2014-01-09
Aravis–College Group: public relations, 201401 service existent by College Hill Life Sciences 2014-01-09
Gen Ilac–Apeiron: APN311, 201401– license €na excl rights to market + sell APN311 in Turkey 2014-01-09
Index Ventures–Lonza: biologicals contract manufacturing, 201401– service 5y developm + manufacture of biologics for portfolio firms of Index Ventures 2014-01-09
Medison Pharma–Apeiron: APN311, 201401– license €na excl rights to market + sell APN311 in Israel 2014-01-09
Merck (DE)–Eurofins: investment, 201401 acquisition of Merck Millipore DDS business by Eurofins 2014-01-09
Roche–Santaris Pharma: LNA technology, 201401– collab $10m upfront + $138m milestones + royalties ww discovery + developm of RNA-targeted medicines 2014-01-09
Bayer–Peking Univ: drug discovery, 201401– collab 3-year establishment of joint research center BPC/TRDD in Beijing 2014-01-08
Isarna Therapeutics–Santaris Pharma: LNA technology, 201401– license for use to discovery + develop + market TGF beta targeting immunotherapies 2014-01-08
Nestlé–Cellular Dynamics: cell research products, 201401– supply €na long-term of iCell + MyCell products to Nestlé Institute of Health Sciences 2014-01-08
Boehringer–Crystal Bioscience: therapeutic antibodies, 201401– collab discovery + developm for multiple targets 2014-01-07
Isarna Therapeutics–MIG Fonds: investment, 201401 financing round €13m from AT NewTec + MIG-managed funds 2014-01-07
Isarna Therapeutics–SEVERAL: investment, 201401 financing round €13m from AT NewTec + MIG-managed funds 2014-01-07
Isarna Therapeutics–Strüngmann Group: investment, 201401 financing round €13m from AT NewTec + MIG-managed funds 2014-01-07
Thermo Fisher–General Electric: investment, 201401–201403 acquisition $1.06b cell culture media + sera + gene modulation + magnetic beads businesses 2014-01-06
AstraZeneca–Probiodrug: CDK9 inhibitors, 201401 acquisition €na of CDK9 inhibitor program by AstraZeneca 2014-01-03
Aettis–Medigene: investment, 2014 spin-off of Aettis from Catherex with Medigene receiving 39% shareholding in Aettis 2014-01-01
CeeTox–Cyprotex: investment, 201401 acquisition of assets + business of CeeTox by Cyprotex 2014-01-01
Dinkelberg Analytics–Altmann Analytik: investment, 201401 acquisition 2014-01-01
Helmholtz–NN: mass spectrometer, 2014 supply PLANNED installation of SIMS at UFZ in Leipzig 2014-01-01
Horizon Discovery–ERS Genomics: CRISPR technology, 2014– license ww non-excl to Horizon 2014-01-01
Laboratorios LETI–Curetis: Unyvero system, 201401– distribution excl in Spain + Portugal by Laboratorios LETI 2014-01-01
Padlock Therapeutics–Evotec: drug discovery services, 201401–201412 collab to deliver multiple PAD inhibitor development candidates 2014-01-01
Peqlab–VWR International: investment, 2014 acquisition of Peqlab Biotechnologie GmbH inkl Clemens GmbH by VWR 2014-01-01
Proteome Sciences–Thermo Fisher: mass spectrometer, 201401 supply installation Orbitrap Fusion MS as part of license deal w Thermo 2014-01-01
Provecs–Cevec: rec protein production technology, 2014– license to CAP GT technology for cancer immunotherapy 2014-01-01
Sirion Biotech–LaVoieHealthScience: public relations, 2014– supply service US PR/IR 2014-01-01
Tusk Therapeutics–Droia Oncology Ventures: investment, 201809 existent majority shareholder + founding investor 2014-01-01
Biognosys–OTHER: credit, 201312 convertible loan $1m 2013-12-31
Optronik–Carl Zeiss: investment, 201312 acquisition 100% of former excl Turkish distribution partner by Carl Zeiss Meditec 2013-12-31
Sirion Biotech–Cevec: cell lines, 201312– license €na to CAP cell lines for expression of AAV vectors 2013-12-19
Boehringer–Circuit Therapeutics: drug target discovery, 201312– collab research €na 3y in field of psychiatric disorders 2013-12-18
Merck (DE)–CNIO: ATR kinase inhibitor, 201312– license excl rights to develop + commercialise ATR kinase inhibitors to Merck Serono 2013-12-18
Structural Genomics Consortium–Bayer: epigenetics, 201312– collab Bayer HealthCare joins SGC as new member 2013-12-18
Emergent BioSolutions–Minapharm: AGE1.CR cell line, 201312– license expansion €na broad non-excl commercial multi-product from ProBioGen 2013-12-17
Automation Partnership–Sartorius: investment, 201310–201312 acquisition €33m in cash of TAP Biosystems Group plc by Sartorius Stedim Biotech GmbH 2013-12-16
Pfizer–Siemens: companion diagnostics, 201312– collab developm + commercialisation master agreement w Siemens Healthcare Diagnostics Inc 2013-12-16
Strüngmann Group–Formycon: biosimilar, 201312– license ww excl to Lucentis biosimilar FYB201 to Santo Holding GmbH 2013-12-12
Roche–Prothena: therapeutic antibodies, 201312– collab ww co-develpm + co-promotion up to $600m + royalties ABs against Parkinson’s 2013-12-11
Covagen–SEVERAL: investment, 201312 tranched Series B CHF42m with option to obtain additional CHF14m led by new investor Gimv 2013-12-09
Biocartis–VIB: molecular diagnostics cancer test, 201312– license €na microsatellite instability (MSI) biomarkers from VIB for cancer tests 2013-12-06
Bayer–Druggability Technologies: drug delivery technology, 201312– collab multi-year to deploy Super-API platform to Bayer HealthCare molecules 2013-12-05
FN Semillas–Bayer: investment, 201312 acquisition €na by Bayer CropScience 2013-12-05
Sonic Healthcare–Ariosa Diagnostics: Harmony Prenatal Test, 201312 supply existent Sonic Healthcare offers test via TDL in the UK 2013-12-05
Sonic Healthcare–Ariosa Diagnostics: Harmony Prenatal Test, 201312– supply Sonic Healthcare will offer test via Bioscientia in Germany 2013-12-05
Euroimmun–Mecklenburg-Vorpommern (govt): grant, 201312– grant €3.15m to support total Euroimmun €14m investment to expand Dassow facility 2013-12-04
Roche–Molecular Partners: DARPins, 201312–201507 collab + license CHF55m upfront + CHF1b milestones + royalites cancer DARPin-toxin TERMINATED 7/15 2013-12-04
Thermo Fisher–SEVERAL: credit, 201312 sale $1b 4.15% Senior Notes due 2024 to part-finance Life Technologies acquisition 2013-12-04
Thermo Fisher–SEVERAL: credit, 201312 sale $400m 5.3% Senior Notes due 2044 to part-finance Life Technologies acquisition 2013-12-04
Thermo Fisher–SEVERAL: credit, 201312 sale $900m 1.3% Senior Notes due 2017 to part-finance Life Technologies acquisition 2013-12-04
Thermo Fisher–SEVERAL: credit, 201312 sale $900m 2.4% Senior Notes due 2019 to part-finance Life Technologies acquisition 2013-12-04
Pfizer–Protagen: biomarker discovery services, 201312– collab use SeroTag process to identify markers for autoimmune drug developm 2013-12-03
Sigma-Aldrich–Glantreo: LC column technology, 201312 collab developm + license Ecoprous silica manufacturing process 2013-12-03
Telormedix–SEVERAL: investment, 201312 financing round Series B extension CHF6m ($6.6m) from existing investors Aravis Venture + ProQuest Investments 2013-12-02
Paion–Capital Ventures International: investment, 201312–201402 private placement €6.17 acquisition 2.55m new shares in 2 tranches by CVI 2013-12-01
TocopheRx–Merck (DE): investment, 201312 seed financing $3.2m from MS Ventures for spin-off from Merck Serono 2013-12-01
Algeta–Bayer: investment, 201311– acquisition proposal by Bayer NOK362/share valuing Algeta equity at €2.1b 2013-11-26
Gilde Investment–SEVERAL: investment, 201311 final close of €145m Gilde Healthcare III fund 2013-11-26
R-Pharm–Paion: remimazolam, 201310– license excl €1m upfront + €3m milestones + royalties for developm + manuf + marketing in Russia + CIS 2013-11-26
R-Pharm–Paion: remimazolam, 201311– license €1m upfront + €3m milestones + royalties for developm + marketing in Turkey to TR-Pharm 2013-11-26
Eloxx Pharmaceuticals–SEVERAL: investment, 201311 initial closing of 1st financing round with Roche + Pontifax 2013-11-21
Boehringer–Galapagos: drug discovery, 201311– supply integrated drug discovery services by BioFocus to undisclosed Boehringer target 2013-11-20
Definiens–Affect: public relations, 201311 service existent by Affect Inc 2013-11-20
GAS GmbH–Imspex: investment, 201311 acquisition of 100% of G.A.S. by Imspex Diagnostics Ltd 2013-11-20
Global Bioenergies–Germany (govt): grant, 201311– BMBF grant €5.7m for Global Bioenergies GmbH within BioEconomy programme 2013-11-20
Merck (DE)–Biopharm: therapeutic protein, 201311– collab €na r+d biopharmaceutical for osteoarthritis with Merck Serono 2013-11-20
Metamark Genetics–Definiens: image analysis s/w, 201311– collab + supply multi-year agreem to use Cognition Network Technology with ProMark test 2013-11-20
CI3 Cluster–AbbVie: personalised immunotherapy, 201311 collab existent AbbVie Deutschland GmbH & Co KG is cluster partner 2013-11-19
CI3 Cluster–Bayer: personalised immunotherapy, 201311 collab existent Bayer Vital GmbH is cluster partner 2013-11-19
next pagenext page 1 2 3 ... 29 30 31 ... 54 55 56  next pagenext page


Picture [LSE] – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px

» top